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The main purpose of the present study was to develop ocuserts of Fluconazole β-CD (beta-cyclodextrin) complex and to evaluate
both in vitro and in vivo. Fluconazole was made complex with β-CD, and the release rate was controlled by HPMC K4Ma n d
ethyl cellulose polymers using dibutyl Phthalate as permeability enhancer. Drug-polymer interactions were studied by Fourier
transform infrared spectroscopic studies. The formulated ocuserts were tested for physicochemical parameters of in vitro release
and in vivo permeation in rabbits. The optimized formulations (F-5 and F-8) were subjected to stability studies. The formulated
ocuserts were found to have good physical characters, thickness, diameter, uniformity in weight, folding endurance, less moisture
absorption, and controlled release of drug both in vitro and in vivo. The optimized formulations retained their characteristics even
after stability studies. The study clearly showed that this technique was an eﬀective way of formulating ocuserts for retaining the
drug concentration at the intended site of action for a suﬃcient period of time and to elicit the desired pharmacological response.
1.Introduction
Eye drops and eye ointments are conventional ocular dosage
forms. They have certain disadvantages like frequent admin-
istration, poor availability, massive and unpredictable doses,
and drainage of medication by tear/nasolacrimal ﬂuid [1–3].
Ocuserts (ophthalmic inserts) are sterile preparations, with
solid or semisolid ingredients with suitable size and shape
especially designed for ophthalmic purpose [4–6]. They are
mainly composed of a polymeric support with drug (s)
incorporatedasdispersionorasolution[7–9].Fluconazole,a
syntheticantifungalagent,isatriazolederivative.Itisusedin
the treatment of a wide range of fungal infections [10], and it
belongs to class II of biopharmaceutical classiﬁcation system
(BCS) having low water solubility [11]. Cyclodextrins (CDs)
are cyclic torus-shaped molecules with a hydrophilic outer
surface and a lipophilic central cavity. CDs are available as
α, β,a n dγ forms. Among them β-CD is popularly included,
which greatly modiﬁes the physical and chemical properties
of the drug molecule, mostly in terms of water solubility.
Inclusion compounds of Cyclodextrin with hydrophobic
molecules are able to penetrate into body tissues; these
can be used to release biologically active compounds under
speciﬁc conditions [12]. It was aimed to prepare ocular ﬁlms
containing Fluconazole β-CD complex.
2.MaterialsandMethods
2.1. Materials. Fluconazole was gift samples from Waksman
and Selman Pharmaceuticals, Anantapur, India. β-CD, acetic
acid, and dibutyl phthalate were procured from Merck
chemicals, Goa, India. All other reagents and solvents were
of analytical grade.
2.2. Preparation of Ocuserts. The preparation of ocuserts
involved three diﬀerent steps [13].
2.2.1. Preparation of Drug Reservoir Film. The polymeric
drug reservoir ﬁlms were prepared by dissolving 1.0, 1.5,2 ISRN Pharmaceutics
and 2.0% of HPMC-K4Mi n1 5m Lo fd o u b l ed i s t i l l e dw a t e r .
Along with this 26.95mg of binary mixture containing
Fluconazole β-CD was separately dissolved in dilute alkali
hydroxide solution and then it was poured to the polymeric
solution. The solution was stirred using magnetic stirrer
at 100rpm, and dibutyl phthalate (10% w/w) (which was
previouslyoptimizedforitsconcentration)wasincorporated
(which serves as both plasticizer and permeation enhancer)
to the above solution under same stirring conditions.
After complete mixing the solution was cast in Petri
dish (previously lubricated with Glycerin) using a ring of
5.0cm diameter and with a funnel inverted on the surface
(for uniform evaporation of solvent). The cast solution was
allowed to evaporate by placing it inside a hot air oven
maintained at 37 ± 2◦C, 30 ± 0.5% of RH for 24 hours.
After drying the medicated ﬁlms of 8mm diameter each
containing 300mg of drug were cut using a stainless steel
borer, which is previously sterilized.
2.2.2. Preparation of Rate Controlling Membrane (RCM). A
weighed quantity of ethyl cellulose was dissolved in 10mL
of acetone to obtain 4, 5, and 6% polymeric solutions.
Stirring wascontinuously maintained until the clearsolution
was obtained. These solutions were poured in Petri dish
(previously lubricated with Glycerin) using a ring of 5.0cm
diameter. The solution was evaporated slowly by inverting a
glassfunnelonapetridishatroomtemperaturefor12hours.
Thedriedﬁlmswerecutinto9mmdiameterusingastainless
steel borer.
2.2.3. Sealing. A medicated reservoir disc was sandwiched
between two rate controlling membranes. Then this whole
unit was placed for 4-5min over a wire mesh inside
the desiccator. Desiccator was previously saturated with
ethanol/acetone (60:40). This procedure resulted into suc-
cessful sealing of the medicated reservoir ﬁlm between two
rate controlling membranes. The sealed ocuserts were stored
in an airtight container under ambient conditions.
Plasticizer weight was based on the weight of the
polymer. All the above experimentation was carried out
under laminar airﬂow to maintain the sterility conditions of
ophthalmic products. The composition of ocusert formula-
tions was represented in Table 1 and shown in Figure 1.
3. Evaluation of Polymeric Ocuserts
3.1. Compatibility Studies. The compatibility of drug with
the excipient used was studied by Fourier transform
infrared (FTIR) spectroscopy. The FTIR spectrums of Flu-
conazole and Formulation (F-5) blend were studied by
using FTIR spectrophotometer (Perkin Elmer, spectrum-
100, Japan) using the KBr disk method (5.2510mg sample
in 300.2502mg KBr). The scanning range was 500 to
4000cm−1, and the resolution was 1cm−1. This spectral
analysis was employed to check the compatibility of drugs
with the polymers used.
Table 1: Composition of various polymers in diﬀerent formula-
tions per ring.
Formulation HPMC-K4M
(%w/v)
EC
(%w/v)
Dibutyl
phthalate
(%v/w)
Fluconazole
β-CD (mg)
F-1 1.0 4.0 10.0 300
F-2 1.0 5.0 10.0 300
F-3 1.0 6.0 10.0 300
F-4 1.5 4.0 10.0 300
F-5 1.5 5.0 10.0 300
F-6 1.5 6.0 10.0 300
F-7 2.0 4.0 10.0 300
F-8 2.0 5.0 10.0 300
F-9 2.0 6.0 10.0 300
12mL of the cast solution was poured into petri dish to prepare circular cast
ﬁlm.
Figure 1: Various formulations of ocuserts.
3.2. Physical Characterization. T h eo c u s e r t sw e r ee v a l u a t e d
for their physical characters such as shape, colour, texture,
and appearance.
3.2.1. Thickness of Film. Films were evaluated for the thick-
ness using a vernier caliper (For-bro Engineers, Mumbai,
India).Theaverageof5readingswastakenatdiﬀerentpoints
of ﬁlm, and the mean thickness was calculated. The standard
deviations (SDs) in thickness were computed from the mean
value [14].
3.2.2. Uniformity in Drug Content. For drug content unifor-
mity, the ocuserts were placed in 5mL of pH 7.4 phosphate
buﬀer saline and were shaken in orbital shaker incubator at
50rpm to extract the drug from ocuserts. After incubation
for24h,thesolutionwasﬁlteredthrougha0.45μmﬁlterand
the ﬁltrate was suitably diluted with buﬀer solution [15, 16].
The absorbance of the resulting solution was measured at
254nm.
3.2.3. Uniformity of Weight. The weight variation test was
carried out using electronic balance (Sartorius GmbH,ISRN Pharmaceutics 3
Gottingen, Germany), by weighing three patches from
each formulation. The mean value was calculated, and the
standard deviations of weight variation were computed from
the mean value.
3.2.4. Folding Endurance. A small strip of ocusert was cut
evenly and separately folded at the same place till it breaks.
The number of times the ocusert could be folded at the same
place without breaking gave the folding endurance [17].
3.2.5. Percentage Moisture Absorption. The percentage mois-
tureabsorptiontestwascarriedouttocheckphysicalstability
or integrity of ocular ﬁlms. Ocular ﬁlms were weighed
and placed in a dessicator containing 100mL of saturated
solution of aluminium chloride, and 79.5% humidity was
maintained. After three days the ocular ﬁlms were taken
out and reweighed. The percentage moisture absorption was
calculated using the following equation [18]:
Percentage moisture absorption
=
Final weight −Initial weight
Initial weight
×100.
(1)
3.2.6. Percentage Moisture Loss. The percentage moisture
loss was carried out to check integrity of the ﬁlm at dry
condition.Ocularﬁlmswereweighedandkeptinadessicator
containing anhydrous calcium chloride. After 3 days, the
ocuserts were taken out and reweighed; the percentage
moisture loss was calculated using the following equation
[19, 20]:
Percentage moisture loss
=
Initial weight −Final weight
Initial weight
×100.
(2)
3.2.7. Determination of the Swelling Index and the Surface pH
of the Fluconazole Films in Distilled Water. T h eo c u s e rt sw e r e
coatedonthelowersidewithethylcellulose(toavoidsticking
to the dish) then weighed (W1) and placed separately in petri
dishes containing 25mL of distilled water. The dishes were
stored at room temperature. After 5, 10, 15, 20, 30, 45, and
60 minutes, the ﬁlms were removed and the excess water
on their surface was carefully removed using ﬁlter paper.
The swollen discs were weighed (W2), and the percentage of
swelling was calculated by the following formula [19–21]:
Swelling index =
W2 −W1
W1
×100. (3)
The ﬁlms used for determination of swelling index were used
for determination of their surface pH using universal pH
paper [22].
3.3. In Vitro Drug Release Studies. The ocuserts from each
batch were taken and placed in 15mL vials containing 10mL
of pH 7.4 phosphate buﬀered saline. The vials were placed in
an oscillating water bath at 32 ± 1◦C with 25 oscillations per
minute. 1mL of the drug releasing media was withdrawn at
various time intervals of 1, 2, 4, 8, 12, 16, and 20 hours and
replaced by the same volume of phosphate buﬀer saline pH
7.4. These samples were ﬁltered through 0.45μmm e m b r a n e
ﬁlter.Theﬁltratewasdilutedsuitablywiththebuﬀer[23,24].
The drug was estimated in each batch by double beam UV-
Vis spectrophotometer (Elico SL 210, Mumbai, India) at
254nm. The obtained data was treated with mathematical
kinetic modeling.
3.4. In Vivo Drug Release Study. Out of 5 batches of
formulations F-5 and F-8 were taken for in vivo study on
the basis of in vitro drug release studies. The ocuserts were
sterilized by using UV radiation before in vivo study. The
ocusert and other materials were exposed to UV radiation
for 1 hour. After sterilization, ocuserts were transferred
into polyethylene bag with the help of forceps inside the
sterilization chamber itself. The pure Fluconazole that was
sterilizedalongwithocusertswasanalyzedforpotencybyUV
spectrophotometer at 254nm after suitable dilution with pH
7.4 phosphate buﬀer [25, 26].
Albinorabbitsofeithersex(New-Zealandstrain),weigh-
ing between 2.5–3.0kg, were used for the experiment. The
animals were housed on individual cages and customized
to laboratory conditions for one day (received free access to
food and water).
The ocuserts containing Fluconazole were taken for in
vivo study, which were previously sterilized on the day of
the experiment and were placed into the lower conjunctival
cul-de-sac. The ocuserts were inserted into each of the seven
rabbits and at the same time the other eye of seven rabbits
served as control.
Ocuserts were removed carefully at 1, 2, 4, 8, 12, 16,
and 20 hours and analyzed for drug content as dilution
mentioned in drug content uniformity. The drug remaining
was subtracted from the initial drug content of ocuserts that
will give the amount of drug released in the rabbit eye.
Observation for any fall out of the ocuserts was also recorded
throughout the experiment. After one week of the washed
period the experiment was repeated for two times as before.
3.5. Ocular Irritation. The potential ocular irritation and/or
damaging eﬀects of the ocusert under test were evaluated by
observing them for any redness, inﬂammation, or increased
tear production. Formulation was tested on ﬁve rabbits by
placing the inserts in the cul-de-sac of the left eye. Both
eyes of the rabbits under test were examined for any signs of
irritation before treatment and were observed up to 12 hours
[27].
3.6. Stability Studies. Stability testing has become an integral
part of formulation development. It generates information
on which, proposed for shelf life of drug or dosage forms and
their recommended storage conditions are based.
In the present study, the formulation F-5 was selected
for the study, and ocuserts were packed in amber-colored
bottles tightly plugged with cotton and capped. They were
exposedtovarioustemperatures(60◦,40 ◦,20 ◦,10 ◦,and0 ◦C)4 ISRN Pharmaceutics
Figure 2: Fluconazole pure drug.
Figure 3: Fluconazole and β-CD.
for 30 days. At regular intervals, the ocuserts were taken in
5mL of pH 7.4 phosphate buﬀer saline and were shaken
in orbital shaker incubator at 50rpm to extract the drug
from ocuserts. After incubation for 24h, the solution was
ﬁltered through a 0.45μm ﬁlter, and the ﬁltrate was suitably
diluted with buﬀer solution. The absorbance of the resulting
solution was measured at 254nm [28]. The logarithmic
percent of undecomposed drug was plotted against time,
and decomposition rate constants (K) were obtained at each
temperature. The logarithm of decomposition rate constants
was plotted against reciprocal of absolute temperature and
theresultinglinewasextrapolatedto K at25◦C.Theshelflife
can be obtained by using formula: T90 = 0.104/K at 25◦C.
4. Results andDiscussion
The compatibility of Fluconazole with the polymer used
(β-Cyclodextrin, HPMC, and EC) was studied by FTIR
spectrums (Figures 2, 3, 4, 5,a n d6). The characteristic peaks
in FTIR spectrums of Fluconazole were seen in the FTIR
spectrum of Fluconazole polymer combinations.
The thickness of the formulated ocuserts was uniform
and ranged from 0.16 ± 0.001 to 0.17 ± 0.005mm. The
little variation observed with formulation F-5 might be due
to the more concentration of rate controlling membrane.
The values of uniformity of weight were found to vary
from 15.89 ± 0.028 to 18.48 ± 0.153mg. All formulations
Figure 4: Fluconazole with HPMC.
Figure 5: Fluconazole with EC.
(F-1 to F-9) showed good uniformity in weight. After the
moisture loss the ocuserts showed no change in integrity,
and it ranged from 6.29 ± 0.109 to 9.68 ± 0.045% and
the moisture absorption ranged from 4.78 ± 0.222 to 9.84
± 0.148%. The highest moisture absorption was marked
from formulation F-6 (9.84 ± 0.148%); this may be due to
the presence of larger concentration of hydrophilic polymer
HPMC-K4M.Thefoldingendurancerangedfrom74 ±6.681
to 98 ± 5.621, and no cracks were observed. Formulations
F-9, F-3, and F-8 showed maximum folding endurance.
The formulated ocuserts were found to have uniformity in
drug content: formulation F-4 showed the least drug content
(85.65 ± 9.657%) and formulation F-9 showed the highest
drug content (97.26 ± 2.255%). The surface pH values of
all ﬁlms were in the range 4.5–6.5. All these values were
represented in Table 2.
Water uptake studies were performed for optimized
formulations (F-5 and F-8). The water uptake was gradually
increasing with time indicating the good wetting nature of
the ocuserts. Water uptake values of the formulated ocuserts
were shown in Table 3.
Based on the highest regression value (r) ,w h i c hi sn e a r
to unity, the formulations F-1, F-2, F-4, F-6, F-8, and F-
9 followed Higuchi-Matrix kinetics. This suggests the drug
release by swellable polymer matrix through the diﬀusion
of tear ﬂuids. The “n” values of formulations F-1 to F-9
were 0.5652, 0.5329, 0.7126, 0.5984, 0.7687, 0.6295, 0.6985,
0.5987, and 0.7748, respectively. This indicates the release by
non-Fickian diﬀusion mechanism. Cumulative percent drug
release for F-5 and F-8 was found to be 92.31 and 93.03%,ISRN Pharmaceutics 5
Table 2: Physicochemical evaluation of diﬀerent formulations.
Formulation Thickness (mm) Weight uniformity
(mg) Moisture loss (%) Moisture absorption
(%) Folding endurance Drug content (%)
F-1 0.16 ± 0.002 17.55 ± 0.107 7.84 ± 0.015 4.78 ± 0.222 74 ± 6.681 89.51 ± 4.568
F-2 0.16 ± 0.001 16.37 ± 0.109 8.54 ± 0.084 5.35 ± 0.155 85 ± 5.847 91.16 ± 6.593
F-3 0.16 ± 0.004 18.35 ± 0.045 9.68 ± 0.045 6.28 ± 0.169 91 ± 6.656 90.26 ± 2.658
F-4 0.16 ± 0.005 15.89 ± 0.028 6.29 ± 0.109 7.84 ± 0.184 68 ± 5.517 85.65 ± 9.657
F-5 0.17 ± 0.003 16.89 ± 0.116 7.57 ± 0.227 8.94 ± 0.167 74 ± 8.594 89.51 ± 7.215
F-6 0.16 ± 0.004 18.48 ± 0.153 8.52 ± 0.024 9.84 ± 0.148 85 ± 6.849 95.21 ± 4.123
F-7 0.16 ± 0.006 15.98 ± 0.117 7.94 ± 0.087 7.51 ± 0.153 85 ± 6.598 88.32 ± 6.597
F-8 0.16 ± 0.005 16.84 ± 0.157 8.54 ± 0.247 8.15 ± 0.048 91 ± 2.955 95.84 ± 5.648
F-9 0.17 ± 0.005 17.97 ± 0.148 9.19 ± 0.028 9.84 ± 0.058 98 ± 5.621 97.26 ± 2.255
All values were expressed as mean ± S.D; number of trials (n) = 5.
Figure 6: Fluconazole ocusert.
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Figure 7: Zero-order plots.
respectively at 20th hour. The kinetic data was tabulated in
Tables 4, 5, 6, 7,a n d8 and shown in Figures 7, 8, 9, 10,a n d
11.
For in vivo drug release, formulations F-5 and F-8 were
selected based on their uniform drug content and highest in
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Figure 8: First-order plots.
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Figure 9: Higuchi’s plots.6 ISRN Pharmaceutics
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Figure 10: Korsmeyer Peppa’s plots.
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Figure 11: Hixson Crowell’s plots.
Table 3: Water uptake and swelling behavior.
Time (hours) Water uptake (mg)
F-5 F-8
04 . 5 1 ± 0.037 4.59 ± 0.253
16 . 2 9 ± 0.017 5.54 ± 0.214
28 . 4 5 ± 0.158 7.68 ± 0.314
39 . 7 9 ± 0.012 10.15 ± 0.168
4 11.54 ± 0.268 12.35 ± 0.247
5 13.57 ± 0.232 16.18 ± 0.658
All values were expressed as mean ± S.D; number of trials (n) = 5.
vitro drug release. The cumulative percent drug release from
F-5 and F-8 was found to be 90.24% and 87.45% at the 20th
hour, respectively, which is found to be less when compared
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Figure 12: Plots of in vivo cumulative drug release versus time for
F-5 and F-8.
Figure 13: Rabbit with ocusert.
Table 4: Kinetic values obtained from zero-order release proﬁle.
Formulation Slope Regression coeﬃcient (r) k value
F-1 3.5491 0.9056 4.4564
F-2 4.2156 0.9035 5.3535
F-3 4.6656 0.9725 5.2641
F-4 4.2471 0.8946 5.4849
F-5 4.7592 0.9721 5.3749
F-6 4.5875 0.9365 5.5367
F-7 4.5088 0.9358 5.0569
F-8 4.3654 0.9064 5.2698
F-9 4.4845 0.9861 4.8976
to in vitro drug release studies. The in vivo cumulative drug
release versus. time for optimized formulations (F-5 and F-
8)wasshowedinFigure 12.Theocusertswereretainedinthe
rabbit eye during the entire study (Figure 13).
Stability data indicates that the formulations were stable,
no major degradation was found (Table 9), and a shelf life of
1.499 years was assigned to the ocuserts (F-8).ISRN Pharmaceutics 7
Table 5: Kinetic values obtained from ﬁrst order release proﬁle.
Formulation Slope Regression coeﬃcient (r) k value
F-1 0.0287 0.9851 −0.0721
F-2 0.0265 0.9638 −0.1231
F-3 −0.0659 0.9691 −0.1251
F-4 −0.0535 0.9947 −0.1168
F-5 −0.0059 0.8446 −0.2059
F-6 −0.0735 0.9646 −0.1464
F-7 −0.0651 0.8945 −0.1443
F-8 −0.0655 0.9259 −0.1498
F-9 −0.0559 0.9548 −0.1053
Table 6: Kinetic values obtained from Higuchi-matrix release
proﬁle.
Formulation Slope Regression coeﬃcient (r) k value
F-1 18.026 0.9964 15.105
F-2 21.854 0.9934 49.534
F-3 21.489 0.9816 19.779
F-4 20.175 0.9946 19.549
F-5 21.816 0.9847 20.765
F-6 22.168 0.9916 20.146
F-7 22.016 0.9894 20.149
F-8 21.534 0.9916 20.146
F-9 21.146 0.9679 19.243
Table 7: Kinetic values obtained from Korsmeyer Peppa’s release
proﬁle.
Formulation Slope Regression coeﬃcient (r) k value n value
F-1 0.4998 0.9995 16.489 0.5652
F-2 0.5334 0.99749 18.754 0.5329
F-3 0.7649 0.9967 10.325 0.7126
F-4 0.5502 0.9969 17.984 0.5984
F-5 0.7449 0.9895 10.987 0.7687
F-6 0.6194 0.9946 16.028 0.6295
F-7 0.7743 0.9685 14.987 0.6985
F-8 0.5764 0.9765 17.961 0.5987
F-9 0.7716 0.9962 8.9986 0.7748
5. Conclusion
Inthepresentstudyanattemptwasmadetodevelopocuserts
of Fluconazole with improved bioavailability, avoidance
of repeated administration and dose reduction. From the
experimental ﬁnding, it can be concluded that Hydroxy
Propyl methyl cellulose is a good ﬁlm forming hydrophilic
polymer and is a promising agent for ocular delivery. Ethyl
cellulose was a satisfactory polymeric ingredient to fabricate
the rate controlling membrane of the ocusert system. Incor-
poration of dibutyl phthalate enhances the permeability of
Fluconazole, and thus therapeutic levels of the drug could be
achieved. Complexation of Fluconazole with β-cyclodextrin
Table 8: Kinetic values obtained from Hixson Crowell’s release
proﬁle.
Formulation Slope Regression coeﬃcient (r) k value
F-1 0.0709 0.9749 −0.0215
F-2 −0.1527 0.9369 −0.0248
F-3 −0.1029 0.9854 −0.0268
F-4 −0.1016 0.9785 −0.0351
F-5 −0.1546 0.9359 −0.0246
F-6 −0.1239 0.9547 −0.0346
F-7 −0.1129 0.9358 −0.0392
F-8 −0.1326 0.9847 −0.0246
F-9 −0.1264 0.9958 −0.0385
Table 9: Data obtained from stability studies.
Temp. (◦C) Ab. Temp (T)R e c T D.R.C. (K)L o g K
60 333 0.00305 0.00164 −2.78516
40 313 0.00319 0.00179 −2.74715
20 293 0.00341 0.00059 −3.22915
10 283 0.00353 0.00036 −3.44369
0 273 0.00366 0.00028 −3.55284
25 298 0.00335 0.00019 −3.72125
Temp: Temperature; Ab. Temp = Absolute Temperature; Rec T:r e c i p r o c a l
of absolute temperature; D.R.C. (K): decomposition rate constant (Day−1);
Log K: logarithm of decomposition rate constant.
suggested enhancing the solubility proﬁle of poorly soluble
drug Fluconazole and also permeability of the drug through
cornea. The kinetic treatment of in vitro dissolution data
indicated that the ocusert followed non-Fickian diﬀusion
kinetics. In vivo release proﬁle indicated that drug release
was less compared to in vitro release, and there was complete
absence of eye irritation and redness of the rabbit eye.
The drug remained intact and stable in the ocuserts on
storage and shelf life of 1.499 years. Further future work
will be progressed to establish the therapeutic utility of these
systems by pharmacokinetic and pharmacodynamic studies
in human beings.
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